文献速递MDS 与骨髓增殖性肿瘤白血病

寡单核细胞型慢性粒单核细胞白血病的结果与分子特征支持将其视为CMML连续病程的第一阶段

Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum.
PubMed 文献 · Blood Adv · 2022-01-01

研究比较42例寡单核细胞型慢性粒单核细胞白血病(OM-CMML)与162例CMML(含120例增生异常型D-CMML和42例增生型P-CMML)的生存结局。OM-CMML的总生存和无急性髓系白血病生存均显著长于CMML整体组、D-CMML组和P-CMML组。中位随访53.47个月时29.3%的OM-CMML进展为D-CMML,中位随访46.03个月时28.6%的D-CMML进展为P-CMML,支持OM-CMML、D-CMML和P-CMML构成演化连续体。

要点

  • OM-CMML的总生存和无急性髓系白血病生存显著长于CMML整体、D-CMML和P-CMML。
  • ASXL1和RAS通路突变是OM-CMML总生存的独立不良预后因素。
  • 突变基因超过3个、携带ASXL1突变、外周血单核细胞百分比>20%显著预测OM-CMML进展为显性CMML。

核心结论

  • 数据支持将OM-CMML视为CMML增殖连续病程中的第一个演化阶段。

研究设计与样本

  • 研究纳入42例OM-CMML患者,并与162例CMML患者(120例D-CMML和42例P-CMML)进行比较。

主要发现

  • OM-CMML的总生存和无急性髓系白血病生存显著长于CMML整体组、D-CMML组和P-CMML组。
  • 中位随访53.47个月时,29.3%的OM-CMML患者进展为D-CMML;中位随访46.03个月时,28.6%的D-CMML组患者进展为P-CMML。
  • ASXL1和RAS通路突变被确定为OM-CMML总生存的独立不良预后因素。
  • 突变基因超过3个、携带ASXL1突变和外周血单核细胞百分比>20%显著预测OM-CMML进展为显性CMML的时间更短,这些变量也是OM-CMML总生存的独立不良预后因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with oligomonocytic chronic myelomonocytic leukemia (OM-CMML) are currently classified according to the 2017 World Health Organization myelodysplastic syndromes classification. However, recent data support considering OM-CMML as a specific subtype of chronic myelomonocytic leukemia (CMML), given their similar clinical, genomic, and immunophenotypic profiles. The main purpose of our study was to provide survival outcome data of a well-annotated series of 42 patients with OM-CMML and to compare them to 162 patients with CMML, 120 with dysplastic type (D-CMML), and 42 with proliferative type (P-CMML). OM-CMML had significantly longer overall survival (OS) and acute myeloid leukemia-free survival than did patients with CMML, considered as a whole group, and when compared with D-CMML and P-CMML. Moreover, gene mutations associated with increased proliferation (ie, ASXL1 and RAS-pathway mutations) were identified as independent adverse prognostic factors for OS in our series. We found that at a median follow-up of 53.47 months, 29.3% of our patients with OM-CMML progressed to D-CMML, and at a median follow-up of 46.03 months, 28.6% of our D-CMML group progressed to P-CMML. These data support the existence of an evolutionary continuum of OM-CMML, D-CMML, and P-CMML. In this context, we observed that harboring more than 3 mutated genes, carrying ASXL1 mutations, and a peripheral blood monocyte percentage >20% significantly predicted a shorter time of progression of OM-CMML into overt CMML. These variables were also detected as independent adverse prognostic factors for OS in OM-CMML. These data support the consideration of OM-CMML as the first evolutionary stage within the proliferative continuum of CMML.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Calvo X, Roman-Bravo D, Garcia-Gisbert N, et al. Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum. Blood Adv. 2022. PMID: 35709473. doi:10.1182/bloodadvances.2022007359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。